{"id":"p-gemox","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL31561","moleculeType":"Small molecule","molecularWeight":"106.17"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This regimen pairs gemcitabine, a nucleoside analog that disrupts DNA replication, with oxaliplatin, a platinum-based agent that forms DNA crosslinks. Together, these agents work synergistically to prevent cancer cell proliferation and survival. The combination is designed to improve efficacy over single-agent therapy in solid tumors.","oneSentence":"P-Gemox is a combination chemotherapy regimen that combines gemcitabine and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:25:13.466Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (specific indication under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT06314334","phase":"PHASE2","title":"Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-04","conditions":"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type","enrollment":210},{"nctId":"NCT05171647","phase":"PHASE3","title":"A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-04-25","conditions":"Non-Hodgkin Lymphoma","enrollment":208},{"nctId":"NCT04127227","phase":"PHASE2","title":"Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2019-10-09","conditions":"NK/T Cell Lymphoma Nos","enrollment":34},{"nctId":"NCT07385989","phase":"PHASE2","title":"Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"WEI XU","startDate":"2026-01-25","conditions":"Extranodal NK/T-cell Lymphoma","enrollment":40},{"nctId":"NCT03533582","phase":"PHASE3","title":"Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-24","conditions":"Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma","enrollment":537},{"nctId":"NCT06953739","phase":"PHASE3","title":"A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL.","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-05-01","conditions":"NK-T-Cell Lymphoma, Extranodal","enrollment":60},{"nctId":"NCT04365036","phase":"PHASE3","title":"A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-05-03","conditions":"NK/T Cell Lymphoma Nos","enrollment":207},{"nctId":"NCT06824883","phase":"PHASE2","title":"Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-05-20","conditions":"Extranodal NK/T-cell Lymphoma","enrollment":49},{"nctId":"NCT06583083","phase":"PHASE2","title":"Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-10-22","conditions":"Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type","enrollment":84},{"nctId":"NCT06573151","phase":"PHASE2","title":"Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-09-01","conditions":"Lymphoma","enrollment":28},{"nctId":"NCT05254899","phase":"PHASE2","title":"Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2021-10-01","conditions":"Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type, Early-stage, High-Risk Cancer","enrollment":54},{"nctId":"NCT02359162","phase":"PHASE3","title":"Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2015-05","conditions":"Lymphoma, Extranodal NK-T-Cell","enrollment":50},{"nctId":"NCT02533323","phase":"PHASE2","title":"P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2012-01","conditions":"Lymphoma, Extranodal NK-T-Cell","enrollment":50},{"nctId":"NCT01308840","phase":"PHASE2","title":"Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2010-12","conditions":"Biliary Tract Cancer, Gallbladder Cancer","enrollment":31},{"nctId":"NCT01389414","phase":"PHASE2","title":"Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX)Versus GEMOX Alone to Treat Advanced Biliary Tract Adenocarcinoma","status":"COMPLETED","sponsor":"Prof. Massimo Aglietta","startDate":"2010-05","conditions":"Biliary Carcinoma","enrollment":89}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":30,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pegaspargase, gemcitabine, oxaliplatin"],"phase":"phase_3","status":"active","brandName":"P-Gemox","genericName":"P-Gemox","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"P-Gemox is a combination chemotherapy regimen that combines gemcitabine and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells. Used for Solid tumors (specific indication under investigation in phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}